Palisade Bio (PALI) director adds 30,000 shares in open-market buys
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Palisade Bio director Robert Baltera Jr. bought a total of 30,000 shares of Palisade Bio common stock in open-market transactions, paying $1.98 per share. The purchases occurred over two days and increased his direct holdings to 366,904 shares.
The filing notes that the reported price is a weighted average, with individual trades executed between $1.97 and $1.99 per share. These transactions represent additional personal investment in the company by a board member, rather than option exercises or compensation-related grants.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 30,000 shares ($59,400)
Net Buy
2 txns
Insider
Baltera Robert Jr.
Role
null
Bought
30,000 shs ($59K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 10,000 | $1.98 | $20K |
| Purchase | Common Stock | 20,000 | $1.98 | $40K |
Holdings After Transaction:
Common Stock — 366,904 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Shares purchased: 30,000 shares
Purchase price: $1.98 per share
Price range: $1.97–$1.99 per share
+2 more
5 metrics
Shares purchased
30,000 shares
Total open-market buys reported in Form 4
Purchase price
$1.98 per share
Reported transaction price for both purchases
Price range
$1.97–$1.99 per share
Weighted-average footnote trade range
Shares owned after
366,904 shares
Director’s direct holdings following transactions
Number of buy transactions
2 transactions
Open-market purchases of common stock
Key Terms
open-market purchase, weighted average price, Reporting Person, Form 4
4 terms
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Reporting Person regulatory
"The Reporting Person undertakes to provide to the Issuer"
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transactions did Palisade Bio (PALI) report in this Form 4?
The Form 4 shows director Robert Baltera Jr. made two open-market purchases totaling 30,000 Palisade Bio common shares at $1.98 each, increasing his direct ownership position to 366,904 shares following the transactions.
Were the Palisade Bio (PALI) insider transactions open-market purchases or option exercises?
The transactions were open-market purchases of common stock, not option exercises. The Form 4 uses transaction code “P” and describes them as purchases in open-market or private transactions, with no derivative securities listed in the derivative summary.